Chemomab Therapeutics (DE:2QV)
FRANKFURT:2QV
2QV Stock Chart & Stats
€2.94
--
Market closed
€2.94
--
Day’s Range― - ―
52-Week Range€2.86 - €4.16
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€10.26M
Enterprise Value€6.40M
Total Cash (Recent Filing)€10.37M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 07, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding7,192,266
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.85
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.96Price Target Upside340.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory De-risking (single Phase 3)Agreement with the FDA on a single Phase 3 registration trial materially reduces development complexity and timeline risk versus multiple trial pathways. This durable regulatory alignment increases the likelihood of efficient path-to-approval, lowers incremental costs, and strengthens appeal to partners and investors over the next 2–6 months.
Robust Translational & Biomarker EvidenceConsistent biomarker, proteomic, and gene-expression signals from the Phase 2 SPRING data provide mechanistic support for disease-modifying effects in PSC and PSC–IBD. Durable scientific validation across conferences and publications improves endpoint selection, de-risks later-stage trials, and enhances partner and payer discussions over the medium term.
Low Leverage On Balance SheetMinimal debt lowers solvency and interest-service risk, preserving operational flexibility while pursuing costly clinical programs. Over several months this structural strength reduces the probability of distress financing, allowing management to prioritize R&D and strategic partnering without heavy fixed financial obligations.
Bears Say
Pre-revenue With Persistent Operating LossesChemomab remains pre-revenue with ongoing operating losses, indicating the business model has not yet generated commercial cash flow. Without successful Phase 3 outcomes and commercialization, the company’s long-term sustainability depends on future clinical success, which is inherently uncertain and extends execution risk over months.
Negative Free Cash Flow & Funding DependencePersistent negative operating and free cash flow mean the company cannot self-fund development and remains reliant on external capital. Even with reduced burn in 2025, funding dependence is a structural vulnerability that could delay trials or force dilutive financings if capital markets tighten, affecting execution across a multi-month horizon.
Eroding Equity And Dilution RiskDeclining equity and assets reflect cumulative losses and prior financings, creating dilution risk for current shareholders. Strongly negative ROE signals value destruction unless pipeline assets convert to revenue, and recent authorization to increase share capital further raises the structural potential for future dilution during fundraising.
Chemomab Therapeutics News
2QV FAQ
What was Chemomab Therapeutics’s price range in the past 12 months?
Chemomab Therapeutics lowest stock price was €2.86 and its highest was €4.16 in the past 12 months.
What is Chemomab Therapeutics’s market cap?
Chemomab Therapeutics’s market cap is €10.26M.
When is Chemomab Therapeutics’s upcoming earnings report date?
Chemomab Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 53 days.
How were Chemomab Therapeutics’s earnings last quarter?
Chemomab Therapeutics released its earnings results on May 14, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of €0 by -€0.003.
Is Chemomab Therapeutics overvalued?
According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued.
Does Chemomab Therapeutics pay dividends?
Chemomab Therapeutics does not currently pay dividends.
What is Chemomab Therapeutics’s EPS estimate?
Chemomab Therapeutics’s EPS estimate is 0.
How many shares outstanding does Chemomab Therapeutics have?
Chemomab Therapeutics has 7,192,266 shares outstanding.
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Chemomab Therapeutics reported an EPS of -€0.003 in its last earnings report, missing expectations of €0. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Chemomab Therapeutics?
Currently, no hedge funds are holding shares in DE:2QV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chemomab Therapeutics
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
2QV Stock 12 Month Forecast
Average Price Target
€12.96
▲(340.77% Upside)
Technical Analysis
Options Prices
Currently, No data available
---